{"id":980973,"date":"2026-07-13T10:43:49","date_gmt":"2026-07-13T14:43:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\/"},"modified":"2026-07-13T10:43:49","modified_gmt":"2026-07-13T14:43:49","slug":"cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\/","title":{"rendered":"Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development"},"content":{"rendered":"

\nPhysician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases
\n<\/h2>\n
\n

BOSTON, July 13, 2026 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development. He reports to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.<\/p>\n

Dr. Borie joins Cue as the company continues to execute its strategy of identifying and advancing through development those immunology programs with potential to offer clinically meaningful improvements for patients. Cue expects Phase 2 CSU data readout for the CUE-221 program by end of third quarter of 2026. In addition, the company remains on track to initiate a Phase 1 clinical trial of CUE-401, its first-in-class bifunctional IL-2 and TGF-\u03b2 molecule with potential for broad applications across autoimmune disease, by the end of the fourth quarter. The company recently announced a $50M private placement to further fund clinical development.<\/p>\n

“Dr. Borie is an outstanding physician-scientist and clinical development leader whose experience spans discovery, development and advancement of innovative therapies for immune-mediated diseases,” said Shao-Lee Lin, M.D., Ph.D., President and Chief Executive Officer of Cue Biopharma. “His deep expertise in immunology and proven leadership across biotechnology and global pharmaceutical organizations will be invaluable as we advance our portfolio of potential new and transformative therapies. I know that Dominic shares our commitment to scientific excellence, collaboration and improving the lives of patients. We are delighted to welcome him to Cue at this exciting stage in the company’s evolution.”<\/p>\n

Dr. Borie brings more than two decades of experience leading research and clinical development organizations in biotechnology and the pharmaceutical industry. Most recently, he served as Strategic Advisor to the CEO and Board of Kyverna Therapeutics, where he previously served as President of Research & Development and founding Chief Executive Officer. Earlier in his career, he held senior leadership positions at Horizon Therapeutics, Genentech, Amgen, and Roche, advancing innovative immunology programs from early development through global clinical studies. Prior to joining industry, he served as Director of the Transplantation Immunology Laboratory at Stanford University and practiced as a transplant surgeon in Paris, France.<\/p>\n

“I am excited to join Cue at such an important time for the company,” said Dr. Borie. “The combination of a differentiated pipeline, a talented and mission-driven team, a solid financial foundation and the opportunity to bring meaningful new therapies to patients with allergic and autoimmune diseases is incredibly compelling. I look forward to working alongside my colleagues to thoughtfully progress on our clinical programs and help realize the full potential of our science for patients.”<\/p>\n

In connection with his appointment, the Compensation Committee of Cue Biopharma’s Board of Directors approved inducement equity awards to Dr. Borie in accordance with Nasdaq Listing Rule 5635(c)(4). The awards, granted as a material inducement to his employment, consist of a non-qualified stock option to purchase 63,000 shares of the Company’s common stock and 31,500 restricted stock units. The option has an exercise price equal to the closing price of the Company’s common stock on the Nasdaq Capital Market on July 13, 2026, and both awards vest over four years, subject to Dr. Borie’s continued employment.<\/p>\n

\n About\u00a0Cue Biopharma<\/strong>
\n
Cue Biopharma (Nasdaq: CUE) is a clinical stage biopharmaceutical company focused on advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its lead asset is a novel anti-IgE antibody with a dual-mechanism of action, currently in Phase 2 development for allergic diseases. In addition, Cue developed the Immuno-STAT\u00ae platform which selectively targets disease-specific T cells in vivo without broad immune modulation. Its lead autoimmune candidate, CUE-401, is advancing towards Phase 1 and was designed to regulate inflammation and drive Treg-mediated tolerance. Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates.<\/p>\n

\n Cautionary Note Regarding Forward-Looking Statements<\/strong>
\n
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the company\u2019s expectations for its newly appointed executive officer and his contributions to the company; and expectations regarding\u00a0the company\u2019s growth, and the company\u2019s business strategies, plans, and prospects. Forward-looking statements, which are based on certain assumptions and describe the company\u2019s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as \u201cbelieve,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cseek,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cgoal,\u201d \u201cproject,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d \u201clikely,\u201d \u201cpromise,\u201d \u201cpotential\u201d or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company\u2019s strategies, prospects, financial condition, operations, costs, plans, and objectives are forward-looking statements. Important factors that could cause the company\u2019s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company\u2019s ability to maintain and establish collaboration, licensing and other arrangements; the company\u2019s limited operating history, limited cash and a history of losses; the company\u2019s ability to obtain adequate financing to fund its business operations in the near term and successfully remediate its current \u201cgoing concern\u201d determination that it does not have sufficient capital on hand to continue operations beyond the next twelve months; the company\u2019s ability to achieve profitability; potential setbacks in the company\u2019s research and development efforts for its current and future drug product candidates, including negative or inconclusive results from its preclinical studies or clinical trials or the company\u2019s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; potential challenges associated with clinical trials conducted in China and the company\u2019s access to, and acceptability of, the data therefrom; its ability to secure required U.S. Food and Drug Administration (\u201cFDA\u201d) or other governmental approvals for its product candidates and the breadth of any approved indication; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company\u2019s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company\u2019s ability to obtain adequate financing to fund its business operations in the future and ability to continue as a going concern; the company\u2019s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the company\u2019s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.<\/p>\n

\n Investor and Media Contact<\/strong>
\n
Agnes Lee
Chief Investor Relations & Communications Officer<\/p>\n

Marie Campinell
Senior Director, Corporate Communications<\/p>\n

ir@cuebio.com<\/a>
Cue Biopharma, Inc.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases BOSTON, July 13, 2026 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development. He reports to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D. Dr. Borie joins Cue as the company continues to execute its strategy of identifying and advancing through development those immunology programs with potential to offer clinically meaningful improvements for patients. Cue expects Phase 2 CSU data readout for the CUE-221 program by end of third quarter of 2026. In … <\/p>\n

Continue reading “Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-980973","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases BOSTON, July 13, 2026 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development. He reports to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D. Dr. Borie joins Cue as the company continues to execute its strategy of identifying and advancing through development those immunology programs with potential to offer clinically meaningful improvements for patients. Cue expects Phase 2 CSU data readout for the CUE-221 program by end of third quarter of 2026. In … Continue reading "Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-13T14:43:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MDg1NSM3NzAyMjcyIzIwOTI2OTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development\",\"datePublished\":\"2026-07-13T14:43:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\\\/\"},\"wordCount\":1258,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MDg1NSM3NzAyMjcyIzIwOTI2OTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\\\/\",\"name\":\"Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MDg1NSM3NzAyMjcyIzIwOTI2OTI=\",\"datePublished\":\"2026-07-13T14:43:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MDg1NSM3NzAyMjcyIzIwOTI2OTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MDg1NSM3NzAyMjcyIzIwOTI2OTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\/","og_locale":"en_US","og_type":"article","og_title":"Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development - Market Newsdesk","og_description":"Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases BOSTON, July 13, 2026 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development. He reports to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D. Dr. Borie joins Cue as the company continues to execute its strategy of identifying and advancing through development those immunology programs with potential to offer clinically meaningful improvements for patients. Cue expects Phase 2 CSU data readout for the CUE-221 program by end of third quarter of 2026. In … Continue reading \"Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-13T14:43:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MDg1NSM3NzAyMjcyIzIwOTI2OTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development","datePublished":"2026-07-13T14:43:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\/"},"wordCount":1258,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MDg1NSM3NzAyMjcyIzIwOTI2OTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\/","name":"Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MDg1NSM3NzAyMjcyIzIwOTI2OTI=","datePublished":"2026-07-13T14:43:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MDg1NSM3NzAyMjcyIzIwOTI2OTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MDg1NSM3NzAyMjcyIzIwOTI2OTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/980973","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=980973"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/980973\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=980973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=980973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=980973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}